Nuo Therapeutics, Inc. AURX
We take great care to ensure that the data presented and summarized in this overview for Nuo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURX
View allLatest Institutional Activity in AURX
Top Purchases
Top Sells
About AURX
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
Insider Transactions at AURX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2025
|
C Eric Winzer Director |
SELL
Payment of exercise price or tax liability
|
Direct |
27,659
-19.03%
|
$27,659
$1.74 P/Share
|
|
Aug 01
2025
|
C Eric Winzer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
120,313
+45.29%
|
$0
$0.4 P/Share
|
|
Aug 01
2025
|
Paul Mintz Director |
SELL
Payment of exercise price or tax liability
|
Direct |
20,115
-22.99%
|
$20,115
$1.74 P/Share
|
|
Aug 01
2025
|
Paul Mintz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
87,500
+50.0%
|
$0
$0.4 P/Share
|
|
Aug 01
2025
|
David Emerson Jorden CEO/CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,313
-0.98%
|
$21,313
$1.74 P/Share
|
|
Aug 01
2025
|
David Emerson Jorden CEO/CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
192,710
+4.35%
|
$0
$0.4 P/Share
|
|
Jul 31
2025
|
Peter Clausen CSO/COO |
BUY
Exercise of conversion of derivative security
|
Direct |
183,853
+19.27%
|
$0
$0.4 P/Share
|
|
Jul 30
2025
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,946
+0.07%
|
$3,946
$1.5 P/Share
|
|
Jul 30
2025
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
133,333
+1.14%
|
$133,333
$1.5 P/Share
|
|
Nov 15
2024
|
Scott M. Pittman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
217,709
+1.34%
|
$0
$0.43 P/Share
|
|
Sep 18
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
125,000
+1.08%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+2.54%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+2.5%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+0.88%
|
$0
$0.75 P/Share
|
|
Dec 19
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.32%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+10.63%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.38%
|
$0
$0.5 P/Share
|
|
Aug 01
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
62,500
+0.56%
|
$125,000
$2.0 P/Share
|
|
Aug 01
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.2%
|
$200,000
$2.0 P/Share
|
|
Aug 01
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+4.34%
|
$50,000
$2.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 802K shares |
|---|---|
| Grant, award, or other acquisition | 3.95K shares |
| Open market or private purchase | 258K shares |
| Payment of exercise price or tax liability | 69.1K shares |
|---|